Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-01-30
1996-08-27
Datlow, Philip I.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514221, 514330, 514563, A61K 31195, A61K 31445, A61K 31535
Patent
active
055501265
ABSTRACT:
Pharmaceutical compositions and methods of using CCK-ligands D,L-glutamic acid and D,L-aspartic acid as antipsychotic, antianxiety, and agents useful in treatment or prevention of withdrawal symptoms caused by withdrawal of chronic or long term use of diazepam, alcohol, cocaine or nicotine and antianxiety agents are described.
REFERENCES:
patent: 4769389 (1988-09-01), Makovec et al.
patent: 4791215 (1988-12-01), Rovati et al.
patent: 4820834 (1989-04-01), Evans et al.
patent: 5004741 (1991-04-01), Evans et al.
patent: 5153191 (1992-10-01), Woodruff
patent: 5391574 (1995-02-01), Makovec et al.
Drug Evaluations, 6th Ed. (1986), Amer. Medical Assn., pp. 111, 113 and 299.
The Merck Index, 11th Ed., Merck & Co., Inc., pp. 383, 472, 594, 1030 (1989).
Bradwejn, J. et al., "Cholecystokinin Tetrapeptide Induces Panic Attacks Identical To Spontaneous Panic Attacks in Patients Suffering from Panic Disorder", Soc. Neurosci. Abstr., vol. 14(1), p. 291 (1988).
de Montigny, C., "Anxiety and Panic Attacks Induced By The Tetrapeptide Cholecystokinin in Healthy Volunteers", Soc. Neurosci. Abstr., vol. 14(1), p. 291 (1988).
Bradwejn, J. and de Montigny, C., "Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones", Nature, vol. 312, pp. 363-364 (1984).
de Montigny, C., "Cholecystokinin Tetrapeptide Induces Panic-like Attacks in Healthy Volunteers", Arch. Gen. Psychiatry, vol. 46, pp. 511-517 (1989).
Dourish, C. T. et al., "Enhancement of morphine analgesia and prevention of morphine tolerance in the art by the cholecystokinin antagonist L-364,718", Eur. Jour. Pharm., vol. 147, No. 3, pp. 469-472 (1988).
O'Neill, M. F. et al., "Morphine Induced Analgesia in the Rat Pressure Test is Blocked by CCK and Enhanced by the CCK Antagonist MK-329", Neuropharmacology, vol. 28, No. 3, pp. 243-247 (1989).
Chang, R. S. L. and Lotti, V. J., "Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist", Proc. Natl. Acad. Sci., vol. 83, pp. 4923-4926 (1986).
Bouthillier A. and De Montigny, C., "Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat", Eur. Jour. Pharm., vol. 151, No. 1, pp. 135-138 (1988).
Schick, et al. Regulatory Peptides, 14:277-291, 1986.
Hill, et al. Neuropharmacology, 26:289-300, 1987.
MacVicar, et al. Brain Research, 406:130-135, 1987.
Roberts, et al. Brain Research, 288, 199-211, 1983.
Totterdell et al. Neuroscience 19, 181-192, 1986.
Weiss, et al. Pharm., Biochem. and Behaviour, 30, 309-317, 1988.
Schneider et al. Peptides 4, 749-753, 1983.
Konturek Gastrointestinal Hormones 23 529-564, 1980.
Johnson ibid. 507-527.
Singh et al. Cancer Research, 46, 1612, 1986.
Smith Gastroenterology 95:1541, 1988.
Dockray Br. Med Bull. 38 No. 3:253-258, 1982.
Morley Life Sciences 27:355-368, 1980.
"CCK in the Nervous System," Belleroche et al, Chichester, England, 110-127, 1984.
Rehfeld et al J. Neurochem. 32:1339-1341, 1979.
Della-Fera et a. Science 206:471-473, 1979.
Demeulemeester et al J. Neuroscience 8:988-1000, 1988.
Harvey The Pharmacological Basis of Therapeutics, (7th ed.) 1985, 339-371, MacMillan.
Wall Street Journal, "Merck Advances in Drug Research to Treat Obesity", Sep. 29, 1989 p. B-4.
Mutt, Gastrointestinal Hormones, Ch. 7, pp. 169-221, Cholecystokinin: Isolation, structure and functions, (1980).
Gastrointestinal Hormones, Fl. Stadil, "Gastrinomas," 1980, pp. 729-739.
Horwell David C.
Hughes John
Woodruff Geoff N.
Bigley Francis P.
Daniel Mark R.
Datlow Philip I.
Merck Sharp and Dohme Limited
LandOfFree
Central cholecystokinin antagonists having pharmaceutical activi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Central cholecystokinin antagonists having pharmaceutical activi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Central cholecystokinin antagonists having pharmaceutical activi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1056300